Key facts
- Arima Genomics’s last known valuation is $41.0M (Jun 2025).
- It has raised $32.7M; the latest was Later Stage VC ($22.0M) in Jun 2025.
- Notable investors include National Institutes of Health, Co-Win Ventures, Illumina Ventures, Ladder Ventures, Agilent Technologies — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Arima Genomics
- ·The full record, as it builds
Funding rounds
No funding rounds for Arima Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Arima Genomics
Developer of a gene-sequencing technology designed to accelerate the understanding of genome sequence and structure toward their role in human health and disease. The company's technology is a proximity ligation method that captures the three-dimensional organizational structure of chromatin, where genomic sequences that are closer to each other in the 3D space can be distal to each in linear distance thereby preserving long-range sequence and structure information before sequencing, enabling scientists to identify structural variants of genes and allow the analysis of critical genetic information.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2015
- Employees
- 49
- Website
- arimagenomics.com/
- Ownership
- Privately Held (backing)
Arima Genomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Arima Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Arima Genomics in its N-PORT filings yet. We sweep new filings monthly.